123 related articles for article (PubMed ID: 10425097)
21. Desferrithiocin analogue iron chelators: iron clearing efficiency, tissue distribution, and renal toxicity.
Bergeron RJ; Wiegand J; Bharti N; McManis JS; Singh S
Biometals; 2011 Apr; 24(2):239-58. PubMed ID: 21103911
[TBL] [Abstract][Full Text] [Related]
22. Effects of desferrithiocin and its derivatives on peripheral iron and striatal dopamine and 5-hydroxytryptamine metabolism in the ferrocene-loaded rat.
Dexter DT; Ward RJ; Florence A; Jenner P; Crichton RR
Biochem Pharmacol; 1999 Jul; 58(1):151-5. PubMed ID: 10403528
[TBL] [Abstract][Full Text] [Related]
23. Methoxylation of desazadesferrithiocin analogues: enhanced iron clearing efficiency.
Bergeron RJ; Wiegand J; McManis JS; Bussenius J; Smith RE; Weimar WR
J Med Chem; 2003 Apr; 46(8):1470-7. PubMed ID: 12672247
[TBL] [Abstract][Full Text] [Related]
24. A comparative evaluation of iron clearance models.
Bergeron RJ; Streiff RR; Wiegand J; Vinson JR; Luchetta G; Evans KM; Peter H; Jenny HB
Ann N Y Acad Sci; 1990; 612():378-93. PubMed ID: 2127168
[TBL] [Abstract][Full Text] [Related]
25. A comparative study of the iron-clearing properties of desferrithiocin analogues with desferrioxamine B in a Cebus monkey model.
Bergeron RJ; Streiff RR; Creary EA; Daniels RD; King W; Luchetta G; Wiegand J; Moerker T; Peter HH
Blood; 1993 Apr; 81(8):2166-73. PubMed ID: 8471775
[TBL] [Abstract][Full Text] [Related]
26. The design of orally active iron chelators.
Hider RC; Zhou T
Ann N Y Acad Sci; 2005; 1054():141-54. PubMed ID: 16339660
[TBL] [Abstract][Full Text] [Related]
27. HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning.
Bergeron RJ; Wiegand J; Brittenham GM
Blood; 2002 Apr; 99(8):3019-26. PubMed ID: 11929795
[TBL] [Abstract][Full Text] [Related]
28. Impact of the 3,6,9-trioxadecyloxy group on desazadesferrithiocin analogue iron clearance and organ distribution.
Bergeron RJ; Wiegand J; Bharti N; Singh S; Rocca JR
J Med Chem; 2007 Jul; 50(14):3302-13. PubMed ID: 17564424
[TBL] [Abstract][Full Text] [Related]
29. The desferrithiocin (DFT) class of iron chelators: potential as antineoplastic agents.
Kicic A; Chua AC; Baker E
Anticancer Drug Des; 2001; 16(4-5):195-207. PubMed ID: 12049478
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological evaluation of hydroxamate-based iron chelators.
Bergeron RJ; Wiegand J; McManis JS; Perumal PT
J Med Chem; 1991 Nov; 34(11):3182-7. PubMed ID: 1956036
[TBL] [Abstract][Full Text] [Related]
31. A non-human primate model for the study of oral iron chelators.
Wolfe LC; Nicolosi RJ; Renaud MM; Finger J; Hegsted M; Peter H; Nathan DG
Br J Haematol; 1989 Jul; 72(3):456-61. PubMed ID: 2765410
[TBL] [Abstract][Full Text] [Related]
32. Iron chelation promoted by desazadesferrithiocin analogs: An enantioselective barrier.
Bergeron RJ; Wiegand J; Weimar WR; McManis JS; Smith RE; Abboud KA
Chirality; 2003 Aug; 15(7):593-9. PubMed ID: 12840823
[TBL] [Abstract][Full Text] [Related]
33. HBED: A potential alternative to deferoxamine for iron-chelating therapy.
Bergeron RJ; Wiegand J; Brittenham GM
Blood; 1998 Feb; 91(4):1446-52. PubMed ID: 9454776
[TBL] [Abstract][Full Text] [Related]
34. Desferrithiocin analogue uranium decorporation agents.
Bergeron RJ; Wiegand J; Singh S
Int J Radiat Biol; 2009 Apr; 85(4):348-61. PubMed ID: 19399680
[TBL] [Abstract][Full Text] [Related]
35. Scaffold Based Search on the Desferithiocin Archetype.
Shyam M; Dev A; Sinha BN; Jayaprakash V
Mini Rev Med Chem; 2019; 19(19):1564-1576. PubMed ID: 30827237
[TBL] [Abstract][Full Text] [Related]
36. Drug evaluation: deferitrin (GT-56-252; NaHBED) for iron overload disorders.
Barton JC
IDrugs; 2007 Apr; 10(4):270-81. PubMed ID: 17390251
[TBL] [Abstract][Full Text] [Related]
37. Preclinical and clinical development of deferitrin, a novel, orally available iron chelator.
Donovan JM; Plone M; Dagher R; Bree M; Marquis J
Ann N Y Acad Sci; 2005; 1054():492-4. PubMed ID: 16339704
[TBL] [Abstract][Full Text] [Related]
38. A comparison of the iron-clearing properties of parabactin and desferrioxamine.
Bergeron R; Streiff RR; King W; Daniels RD; Wiegand J
Blood; 1993 Oct; 82(8):2552-7. PubMed ID: 8400302
[TBL] [Abstract][Full Text] [Related]
39. Synthesis, physicochemical properties, and evaluation of N-substituted-2-alkyl-3-hydroxy-4(1H)-pyridinones.
Rai BL; Dekhordi LS; Khodr H; Jin Y; Liu Z; Hider RC
J Med Chem; 1998 Aug; 41(18):3347-59. PubMed ID: 9719587
[TBL] [Abstract][Full Text] [Related]
40. A Novel iron-chelating derivative of the neuroprotective peptide NAPVSIPQ shows superior antioxidant and antineurodegenerative capabilities.
Blat D; Weiner L; Youdim MB; Fridkin M
J Med Chem; 2008 Jan; 51(1):126-34. PubMed ID: 18078312
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
